The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden-Reference-Cited by-同舟云学术

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

Published:2021-06-03 Issue:8 Volume:39 Page:941-952
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Nilsson Fredrik O. L.^ORCID,Asanin Sandra T.,Masters Elizabeth T.,Iadeluca Laura,Almond Chrissy,Cooper Miranda,Smith Sarah

Funder

Pfizer Inc

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01015-8.pdf

Reference56 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Hallberg B, Palmer RH. ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med Rep. 2011;3:21.

3. Ke L, Xu M, Jiang X, Sun X. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase/oncogene or C-Ros oncogene 1 (ALK/ROS1) fusions inflict non-small cell lung cancer (NSCLC) female patients older than 60 years of age. Med Sci Monit. 2018;24:9364–9.

4. Cancer.Net. Lung cancer—non-small cell: statistics. 2020 [cited 2020 July 28]; https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.

5. Cancerfonden. Cancerfondsrapporten 2018 [cited 2020 July 28]; https://static-files.cancerfonden.se/Cancerfondsrapporten2018_webb_(2)_1521607903.pdf.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15

2. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain;ClinicoEconomics and Outcomes Research;2023-09

3. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC);PharmacoEconomics;2023-06-03

4. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden;Applied Health Economics and Health Policy;2023-05-12

5. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer;Value in Health;2023-01